Want to see DE:SBS full AI Analyst Report?
SBS Stock Chart & Stats
€19.70
€0.28(1.42%)
At close: 4:00 PM EDT
€19.70
€0.28(1.42%)
Day’s Range― - ―
52-Week Range€16.30 - €33.10
Previous CloseN/A
Volume3.37K
Average Volume (3M)15.55K
Market Cap
€237.28M
Enterprise Value€301.10
Total Cash (Recent Filing)€23.74M
Total Debt (Recent Filing)€116.97M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 14, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield3.07%
Share Statistics
EPS (TTM)-0.27
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.00Price Target Upside42.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.39
Revenue Forecast (FY)€263.66M
Bulls Say, Bears Say
Bulls Say
OEM/Recurring Revenue ModelSTRATEC's OEM contract development and manufacturing model embeds the company into customers' product lifecycles, creating recurring instrument production, consumables and aftermarket service revenue. That installed-base linkage supports durable, annuity-like revenue and higher lifetime customer value over multiple years.
Improved Cash GenerationA return to positive operating and free cash flow (Q1 and TTM) strengthens liquidity and funds working capital, capex and R&D without immediate reliance on external financing. Sustained cash generation over several quarters would underwrite investments and reduce leverage risk during the recovery to targeted margins.
Balance Sheet ImprovementA solid equity base and materially reduced leverage provide a financial buffer while earnings recover. Lower net debt and acceptable historic debt ratios give STRATEC flexibility to absorb temporary margin pressure, invest in product development or localize production without immediate solvency stress.
Bears Say
Multi-year Revenue DeclineSustained top-line decline erodes scale economics, reduces throughput-related margins and shrinks the installed base that feeds recurring consumables and service revenue. If the negative trend persists beyond a few quarters it will structurally hinder margin recovery and long-term cash conversion potential.
Margin Compression And Net LossesSharp margin contraction and the swing to net losses indicate scalability and mix problems: lower high-margin consumables and underutilized capacity drive poor operating leverage. Persistent margin weakness would limit reinvestment and make the company’s medium-term EBIT targets harder to achieve without material mix or pricing improvement.
Elevated Inventory & Consumables Visibility RiskVery high inventory and legacy last-time-buy exposure increase obsolescence and working-capital risk, tying up cash and potentially triggering write-downs. Coupled with weak visibility on high-margin consumables orders, this raises the risk that recurring revenue and gross margins will underperform management's guidance in the medium term.
STRATEC Biomedical News
SBS FAQ
What was STRATEC Biomedical AG’s price range in the past 12 months?
STRATEC Biomedical AG lowest stock price was €16.30 and its highest was €33.10 in the past 12 months.
What is STRATEC Biomedical AG’s market cap?
STRATEC Biomedical AG’s market cap is €237.28M.
When is STRATEC Biomedical AG’s upcoming earnings report date?
STRATEC Biomedical AG’s upcoming earnings report date is Aug 14, 2026 which is in 7 days.
How were STRATEC Biomedical AG’s earnings last quarter?
Currently, no data Available
Is STRATEC Biomedical AG overvalued?
According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued.
Does STRATEC Biomedical AG pay dividends?
STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 3.07%. See more information on STRATEC Biomedical AG dividends here
What is STRATEC Biomedical AG’s EPS estimate?
STRATEC Biomedical AG’s EPS estimate is 0.19.
How many shares outstanding does STRATEC Biomedical AG have?
STRATEC Biomedical AG has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of STRATEC Biomedical AG?
Currently, no hedge funds are holding shares in DE:SBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
STRATEC Biomedical Stock Smart Score
Company Description
STRATEC Biomedical AG
Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.
SBS Stock 12 Month Forecast
Average Price Target
€28.00
▲(42.13% Upside)
Technical Analysis
Draegerwerk AG & Co. KGaA
―
Eckert & Ziegler Strahlen und Medizintechnik
―
First Sensor
―
Gerresheimer
―
Siemens Healthineers AG
―



